Breast Cancer

Cancer clinical trials supporting FDA approvals significantly differ in reporting of withdrawal of consent or loss to follow-up and early drug discontinuation for adverse events, according to study results.

Cancer cell-derived or allergic reaction-released histamine dampened antitumor immunity and conferred resistance to cancer immunotherapy, according to a retrospective study published in Cancer Cell.

Patients with cancer had few differences in reported adverse events compared with people without cancer after receiving COVID-19 vaccines, according to study results published in JNCCN — Journal of the National Comprehensive Cancer Network.

The COVID-19 pandemic had significant repercussions on the health care system. As lockdowns went into effect, patients postponed, canceled or simply did not make needed medical appointments.

Women with diabetes were significantly less likely to complete a mammogram than women without the condition, according to an analysis of electronic health records from a single institution.

Lymphedema — swelling in the limbs or trunk caused by excess fluid that can arise following cancer treatment — can be extremely detrimental to survivors’ quality of life.

Lymphedema occurs in around 20% of breast cancer survivors depending on the treatment course, but growing knowledge of risk factors and the importance of early screening can improve these odds.

The FDA granted fast track designation to gedatolisib for treatment of certain patients with breast cancer.

In this video, Angela DeMichele, MD, MSCE, co-leader of the Breast Cancer Research Program and director of the Breast Cancer Clinical Trials Unit at Penn Medicine, spoke with Healio about circulating tumor DNA in breast cancer.

Angela DeMichele, MD, MSCE, co-leader of the Breast Cancer Research Program and director of the Breast Cancer Clinical Trials Unit at Penn Medicine, spoke with Healio about presentations from the 2021 San Antonio Breast Cancer Symposium.